Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Lirussi, Flavio ^a   Azzalini, L ^b   Orando, S ^b   Orlando, R ^b   Angelico, F ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b NONE

Author keywords

*Dietary supplements; Antioxidants *therapeutic use ; Fatty liver blood; *drug therapy ; Humans; Randomized controlled trials as topic

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; CAROTENOID; GAMMA GLUTAMYLTRANSFERASE; RETINOL; SELENIUM;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COCHRANE LIBRARY; EMBASE; FOLLOW UP; HUMAN; LIPID PEROXIDATION; LIVER CELL; LIVER CIRRHOSIS; MEDLINE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; OXIDATIVE STRESS; REVIEW; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 34249053143     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004996.pub3     Document Type: Review

References (46)

1. Bugianesi 2005 {published data only} Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al.A randomized controlled trial of metformin versus Vitamin E or prescriptive diet in nonalcoholic fatty liver disease. American Journal of Gastroenterology 2005;100:1082-90.
2. Harrison 2003 {published data only} Harrison S, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. The American Journal of Gastroenterology 2003;98:2485-90.
3. Miglio 2000 {published data only} Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. Leber-Therapeutika 2000;50(2):722- 7.
4. Pamuk 2003 {published data only} Pamuk GE, Sonsuz A. N-acetylcysteine in the treatment of nonalcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2003;18(10):1220-1.
5. Rui 2001 {published data only} Rui M, Wang C, Fang J, et al.The clinical comparison of reduced glutathione and DanNingPlan in the treatment of nonalcoholic steatohepatitis. Chinese General Practice 2001;4(4):269-70.
6. Vajro 2004 {published data only} Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello, Savoia M, et al.Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. Journal of Pediatric Gastroenterology 2004;38:48-55.
7. Abdelmalek 2001 Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. The American Journal of Gastroenterology 2001;96(9):2711-7.
8. Dentico 1995 Dentico P, Volpe A, Buongiorno R, Grattagliano I, Altomare E, Tantimonaco G, et al.Glutathione in the treatment of chronic fatty liver diseases [Il glutatione nella terapia dell'epatopatie croniche steatosiche]. Recenti Progressi in Medicina 1995;86(7-8):290-3.
9. Hasegawa 2001 Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Alimentary Pharmacology & Therapeutics 2001;15(10):1667-72.
10. Kugelmas 2003 Kugelmas M, Hill D, Vivian B, Marsano L, McClain C. Cytokines and NASH: a pilot study of the effect of lifestyle modification and vitamin E. Liver Failure and Liver Disease 2003;38(2):413-9.
11. Lavine 2000 Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. The Journal of Pediatrics 2000;136(6):734-42.
12. Lu 2005 Lu L, Zeng M, Mao Y, Chen C, Fu Q, Wang J. Diisopropylamine dichloroacetate in the treatment of nonalcoholic fatty liver disease: a multicenter random double-blind controlled trial. Chinese Journal of Hepatology 2005;13(2):92-5.
13. Merat 2003 Merat S, Malekzadeh R, Sohrabi MR, Hormazdi M, Naserimoghadam S, Mikaeli J, et al.Probucol in the treatment of nonalcoholic steatohepatitis. Journal of Clinical Gastroenterology 2003;36(3):266-8.
14. Sanyal 2004 Sanyal A, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al.A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology 2004;2:1107-15.
15. Trappoliere 2005 Trappoliere M, Federico A, Tuccillo C, de Sio I, Di leva A, Niosi M, et al.Effects of new pharmacological complex (sylibin+vitamin E+phospolipids) on some markers of metabolic syndrome and of a liver fibrosis in patients with non-alcoholic fatty liver disease: a preliminary open pilot study. Minerva Gastroenterologica e Dietologica 2005;51:193-9.
16. Dufour 2005 Dufour JF, Oneta C, Gonvers JJ, Bihl F, Cerny A, Cereda JM. A 2-years multicenter randomized placebo-controlled study testing UDCA in combination with vitamin E to treat NASH. Journal of Hepatology 2005;12(Supplement 2):4-5.
17. Angelico 2007 Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD005166. DOI: 10.1002/14651858.CD005166.pub2.
18. Angulo 2002a Angulo P. Nonalcoholic fatty liver disease. New England Journal of Medicine 2002;16:1221-31.
19. Angulo 2002b Angulo P, Lindor KD. Treatment of non-alcoholic steatohepatitis. Best Practice & Research. Clinical Gastroenterology 2002;16(5):797-810.
20. Bacon 1994 Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-9.
21. Becker 1996 Becker U, Deis A, Sorensen TI, Gronbæk M, Borch-Johnsen K, Florvall Muller C, et al.Prediction of risk of liver disease by alcohol intake, sex and age: a prospective population study. Hepatology 1996;23(5):1025-9.
22. Brolin 1998 Brolin RE, Bradley LJ, Taliwal RV. Unsuspected cirrhosis discovered during obesity operations. Archives of Surgery 1998;133:84-8.
23. Brunt 1999 Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. American Journal of Gastroenterology 1999;94(9):2467-74.
24. Caldwell 1999 Calwell SH, Oelsner DH, Iezzoni J, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9.
25. Chitturi 2001 Chitturi S, Farrell GC. Etiopathogenesis of non-alcoholic steatohepatitis. Seminars in Liver Diseases 2001;21:27-41.
26. Chitturi 2002a Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al.NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-9.
27. Clark 2006 Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. Journal of Clinical Gastroenterology 2006;40(3 Suppl 1):S5-S10.
28. DeMets 1987 DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50. [MEDLINE: 87291426].
29. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
30. Farrell 2003 Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. Journal of Gastroenterology and Hepatology 2003;18:124-38.
31. Farrell 2006 Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43(2 Suppl 1):S99-S112.
32. Gluud 2006 Gluud C, Als-Nielsen B, D'Amico G, Fingerhut A, Gluud LL, Khan S, et al.Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2006, Issue 3. Art.No.: LIVER.
33. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4, 2006. Chichester, UK: JohnWiley & sons, Ltd.
34. Jimba 2005 Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, et al.Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetic Medicine 2005;22(9):1141-5.
35. Kjaergard 2001 Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9. [MEDLINE: 21587469].
36. Kleiner 2005 Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313- 21.
37. Liou 2006 Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. Journal of Clinical Gastroenterology 2006;40(3 Suppl 1):S11-S16.
38. McCullough 2002 McCullough AJ. Update on nonalcoholic fatty liver disease. Journal of Clinical Gastroenterology 2002;34(3):255-62.
39. Miller 2005 Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine 2005;142(1):37-46.
40. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported inmeta-analyses?. Lancet 1998;352(9128):609-13. [MEDLINE: 98417104].
41. Neuschwander-T 2003 Neuschwander-Tetri BA, Caldwell ST. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37(5):1202-19.
42. Poonawala 2000 Poonawala A, Nair S, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689-92.
43. RevMan 2003 Copenhagen: TheNordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
44. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions ofmethodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12. [MEDLINE: 95123716].
45. Wang 2002 Wang RT, Koretz RL, Yee HF. Weight reduction for non-alcoholic fatty liver. (Protocol) The Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD003619. DOI: 10.1002/14651858.CD003619.
46. Younossi 2002 Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35(4):746-52.